Enhanced delivery of doxorubicin for breast cancer treatment using pH-sensitive starch/PVA/g-C3N4 hydrogel

Alipournazari, Parisa; Pourmadadi, Mehrab; Abdouss, Majid; Rahdar, Abbas; Pandey, Sadanand

doi:10.1016/j.ijbiomac.2024.130901

Cited by 16 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxorubicin and docetaxel, used in breast cancer therapy, have shown promising results when combined in clinical trials [51]. Doxorubicin intercalates with DNA, which induces apoptosis via DNA synthesis inhibition, which is very effective against solid tumors [52]. On the other hand, docetaxel is a microtubule inhibitor [53].…”

Section: Role Of Filamin a In Dna Repair And Therapy Outcome In Breas...mentioning

confidence: 99%

Role of Filamin A in Growth and Migration of Breast Cancer—Review

Zawadka,

Zielińska,

Gagat

et al. 2024

CIMB

View full text Add to dashboard Cite

Despite ongoing research in the field of breast cancer, the morbidity rates indicate that the disease remains a significant challenge. While patients with primary tumors have relatively high survival rates, these chances significantly decrease once metastasis begins. Thus, exploring alternative approaches, such as targeting proteins overexpressed in malignancies, remains significant. Filamin A (FLNa), an actin-binding protein (ABP), is involved in various cellular processes, including cell migration, adhesion, proliferation, and DNA repair. Overexpression of the protein was confirmed in samples from patients with numerous oncological diseases such as prostate, lung, gastric, colorectal, and pancreatic cancer, as well as breast cancer. Although most researchers concur on its role in promoting breast cancer progression and aggressiveness, discrepancies exist among studies. Moreover, the precise mechanisms through which FLNa affects cell migration, invasion, and even cancer progression remain unclear, highlighting the need for further research. To evaluate FLNa’s potential as a therapeutic target, we have summarized its roles in breast cancer.

show abstract

Section: Role Of Filamin a In Dna Repair And Therapy Outcome In Breas...mentioning

confidence: 99%

Role of Filamin A in Growth and Migration of Breast Cancer—Review

Zawadka,

Zielińska,

Gagat

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

“…Silybin (SIB) comprises 50-70% of the Sili composition and is the principal active component. SIB is a drug that has antioxidant, anti-inflammatory, antifibrotic, and immunomodulatory properties [2,3]. The antioxidant effect occurs through direct or indirect effects on reactive oxygen species, stimulating production of endogenous antioxidant agents [4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Silybin Nanoparticles against Liver Damage in Murine Schistosomiasis mansoni Infection

Vanzan,

Goma,

Locatelli

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Silybin (SIB) is a hepatoprotective drug known for its poor oral bioavailability, attributed to its classification as a class IV drug with significant metabolism during the first-pass effect. This study explored the potential of solid lipid nanoparticles with (SLN-SIB-U) or without (SLN-SIB) ursodeoxycholic acid and polymeric nanoparticles (PN-SIB) as delivery systems for SIB. The efficacy of these nanosystems was assessed through in vitro studies using the GRX and Caco-2 cell lines for permeability and proliferation assays, respectively, as well as in vivo experiments employing a murine model of Schistosomiasis mansoni infection in BALB/c mice. The mean diameter and encapsulation efficiency of the nanosystems were as follows: SLN-SIB (252.8 ± 4.4 nm, 90.28 ± 2.2%), SLN-SIB-U (252.9 ± 14.4 nm, 77.05 ± 2.8%), and PN-SIB (241.8 ± 4.1 nm, 98.0 ± 0.2%). In the proliferation assay with the GRX cell line, SLN-SIB and SLN-SIB-U exhibited inhibitory effects of 43.09 ± 5.74% and 38.78 ± 3.78%, respectively, compared to PN-SIB, which showed no inhibitory effect. Moreover, SLN-SIB-U demonstrated a greater apparent permeability coefficient (25.82 ± 2.2) than PN-SIB (20.76 ± 0.1), which was twice as high as that of SLN-SIB (11.32 ± 4.6) and pure SIB (11.28 ± 0.2). These findings suggest that solid lipid nanosystems hold promise for further in vivo investigations. In the murine model of acute-phase Schistosomiasis mansoni infection, both SLN-SIB and SLN-SIB-U displayed hepatoprotective effects, as evidenced by lower alanine amino transferase values (22.89 ± 1.6 and 23.93 ± 2.4 U/L, respectively) than those in control groups I (29.55 ± 0.7 U/L) and I+SIB (34.29 ± 0.3 U/L). Among the prepared nanosystems, SLN-SIB-U emerges as a promising candidate for enhancing the pharmacokinetic properties of SIB.

show abstract

“…20–23 Biopolymer-based composites play a major role in many applications due to their unique characteristics. 44–50 Epoxy resin not only has good mechanical properties, but amine-cured epoxy resin also has superior dye adsorption performance. 24–26 Therefore, introducing epoxy resin into chitosan can not only improve its mechanical properties but also enhance its adsorption capacity.…”

Section: Introductionmentioning

confidence: 99%